Crescent Biopharma (CBIO)
Nasdaq Market Open
Crescent Biopharma, Inc. is a biopharmaceutical company focused on developing cancer therapies for solid tumours. Its strategy centres on antibody-based medicines, including bispecific antibodies and antibody-drug conjugates, that are designed to improve treatment options in oncology. As a development-stage biotechnology company, Crescent’s value is closely linked to the progress of its pipeline, clinical data, regulatory interactions, and ability to secure funding for research and development.
The company’s lead programme is CR-001, a proprietary bispecific antibody designed to target both PD-1 and VEGF pathways. PD-1 is a key immune checkpoint involved in limiting anti-tumour immune responses, while VEGF is associated with tumour blood-vessel formation and the tumour microenvironment. By combining these mechanisms in one molecule, Crescent aims to create a therapy that could offer meaningful activity in solid tumours where checkpoint inhibition and anti-angiogenic strategies are already important treatment approaches.
CR-001 is described by the company as a new molecular entity intended to reproduce the functional characteristics of ivonescimab, a cooperative anti-PD-1/anti-VEGF bispecific antibody being developed by Akeso Biopharma and Summit Therapeutics. Crescent is also working on CR-002 and CR-003, which are antibody-drug conjugate programmes directed at validated oncology targets.
The company operates in a highly competitive and scientifically complex segment of biotechnology. Its prospects depend on demonstrating safety, efficacy, manufacturability, and differentiation versus established cancer drugs such as immune checkpoint inhibitors and newer bispecific or ADC candidates. Crescent Biopharma therefore offers exposure to high-risk, high-potential oncology drug development.
Last updated
- Market Cap
- 495.8M
- P/E
- —
- P/FCF
- —
- P/S
- 41.72
- Enterprise Value
- 306.63M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 300 FIFTH AVENUE, WALTHAM, MA, 02451
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
Merck (MRK) Gets FDA Fast Track Tag for Anticoagulant Therapy
Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation
Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company’s Nominees on the WHITE Proxy Card
Catalyst Biosciences Publishes New Investor Presentation
Catalyst Biosciences Announces Support from Largest Single Stockholder
Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?
Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?
5 Penny Stocks To Watch With High Short Interest, Are They A Buy Now?
Hot Penny Stocks to Buy This Week? 3 to Watch
Penny Stocks To Buy Now? 3 With Unusual Options Activity To Watch
Penny Stocks To Buy Now? 4 To Watch Under $1
Catalyst Biosciences Sells Complement Portfolio for $60 Million
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology
Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives
Trading Penny Stocks? Top Stock Market News For January 25th, 2022
Catalyst Biosciences, Inc. (CBIO) Upgraded to Buy: Here's What You Should Know
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 495.8M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 306.63M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.7
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 41.72
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -1.88
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 25.8
- EPS
- -5.16
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -76.43M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -77.38%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -71.44%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 13.78
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 13.78
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 13.33
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 317K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 17.98
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 1.04M | 10.84M | — | — | — |
| Gross profit | 1.04M | 10.84M | — | — | — |
| Operating income | -24.73M | -91.49M | -25.89M | -21.03M | -14.22M |
| EBITDA | -24.67M | -91.44M | -25.86M | -21.03M | -14.22M |
| Net income | -21.26M | -81.06M | -20.95M | -19M | -15.15M |
| Basic EPS | -0.7 | -4.92 | -1.27 | -4.93 | -19.63 |
| Diluted EPS | -0.7 | -4.92 | -1.27 | -4.93 | -19.63 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 199.13M | 240.29M | 138.27M | 157.43M | 5.99M |
| Total liabilities | 15.28M | 37.28M | 21.63M | 18.18M | 2.62M |
| Total equity | 183.85M | 203.01M | 116.64M | 139.25M | 3.38M |
| Cash & equivalents | 189.16M | 213.19M | 133.27M | 152.65M | 5.61M |
| Current assets | 195.56M | 236.66M | 134.56M | 154.23M | 5.99M |
| Current liabilities | 14.19M | 36.07M | 20.3M | 16.75M | 2.62M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -8.94M | -26.74M | -17.54M | -22.15M | -10.85M |
| Investing cash flow | -8.15M | -72.19M | -586K | -140K | — |
| Financing cash flow | -6.95M | 178.86M | -1.25M | 145.38M | -1.49M |
| Change in cash | -24.03M | 79.93M | -19.38M | 123.09M | -12.34M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Harwin Peter Evan | View Filing | |
| form 4 | Form 4 — Kiselak Tomas | View Filing | |
| form 4 | Form 4 — Fairmount Healthcare Fund II L.P. | View Filing | |
| form 4 | Form 4 — Fairmount Funds Management LLC | View Filing | |
| form 4 | Form 4 — Moran Susan | View Filing | |
| form 4 | Form 4 — Balcom Alexandra | View Filing | |
| form 4 | Form 4 — Lubner David Charles | View Filing | |
| form 4 | Form 4 — Violin Jonathan | View Filing | |
| edgar index | SCHEDULE 13G — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | SCHEDULE 13G/A — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 10-Q — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 8-K — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 424B3 — CRESCENT BIOPHARMA, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | DEFA14A — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | DEFA14A — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 424B3 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | POS AM — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | EFFECT — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 10-K — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 8-K — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | S-8 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 424B3 — CRESCENT BIOPHARMA, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | SCHEDULE 13G — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | SCHEDULE 13G/A — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | SCHEDULE 13G/A — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 424B3 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | EFFECT — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | CORRESP — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | UPLOAD — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | S-1 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| edgar index | 4 — CRESCENT BIOPHARMA, INC. | View Filing | |
| form 4 | Form 4 — Bispham Barbara Harlin | View Filing | |
| form 4 | Form 4 — Bispham Barbara Harlin | View Filing | |
| form 4 | Form 4 — Bispham Barbara Harlin | View Filing | |
| form 4 | Form 4 — Lynch Ryan | View Filing | |
| form 4 | Form 4 — Lynch Ryan | View Filing | |
| form 4 | Form 4 — Lynch Ryan | View Filing | |
| form 4 | Form 4 — Im Ellie Eunkyung | View Filing | |
| form 4 | Form 4 — Im Ellie Eunkyung | View Filing | |
| form 4 | Form 4 — Im Ellie Eunkyung | View Filing | |
| form 4 | Form 4 — McNeill Jonathan | View Filing | |
| form 4 | Form 4 — McNeill Jonathan | View Filing | |
| form 4 | Form 4 — McNeill Jonathan | View Filing | |
| form 4 | Form 4 — Scalzo Richard William | View Filing | |
| form 4 | Form 4 — Scalzo Richard William | View Filing | |
| form 4 | Form 4 — Scalzo Richard William | View Filing | |
| form 4 | Form 4 — Brumm Joshua T | View Filing | |
| form 4 | Form 4 — Brumm Joshua T | View Filing | |
| form 4 | Form 4 — Brumm Joshua T | View Filing | |
| form 4 | Form 4 — Doughty Christopher Grant | View Filing | |
| form 4 | Form 4 — Doughty Christopher Grant | View Filing | |
| form 4 | Form 4 — Doughty Christopher Grant | View Filing | |
| form 4 | Form 4 — Pinkas Jan | View Filing | |
| form 4 | Form 4 — Pinkas Jan | View Filing | |
| form 4 | Form 4 — Pinkas Jan | View Filing |